Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
About this item
Full title
Author / Creator
SPARTAN Investigators , Smith, Matthew R , Saad, Fred , Chowdhury, Simon , Oudard, Stéphane , Hadaschik, Boris A , Graff, Julie N , Olmos, David , Mainwaring, Paul N , Lee, Ji Youl , Uemura, Hiroji , Lopez-Gitlitz, Angela , Trudel, Géralyn C , Espina, Byron M , Shu, Youyi , Park, Youn C , Rackoff, Wayne R , Yu, Margaret K and Small, Eric J
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Among men with nonmetastatic prostate cancer who had a rapid PSA doubling time and were receiving androgen-deprivation therapy, the median metastasis-free survival was 40.5 months with apalutamide versus 16.2 months with placebo. Rash occurred in 24% of men receiving apalutamide.
Alternative Titles
Full title
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Authors, Artists and Contributors
Author / Creator
Smith, Matthew R
Saad, Fred
Chowdhury, Simon
Oudard, Stéphane
Hadaschik, Boris A
Graff, Julie N
Olmos, David
Mainwaring, Paul N
Lee, Ji Youl
Uemura, Hiroji
Lopez-Gitlitz, Angela
Trudel, Géralyn C
Espina, Byron M
Shu, Youyi
Park, Youn C
Rackoff, Wayne R
Yu, Margaret K
Small, Eric J
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_490638
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_490638
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1715546
